Currently, there are 30.80M common shares owned by the public and among those 29.06M shares have been available to trade.
The company’s stock has a 5-day price change of 29.09% and -84.13% over the past three months. BIOL shares are trading -84.02% year to date (YTD), with the 12-month market performance down to -99.47% lower. It has a 12-month low price of $0.13 and touched a high of $47.10 over the same period. BIOL has an average intraday trading volume of 2.75 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 26.52%, -59.65%, and -93.93% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Biolase Inc (NASDAQ: BIOL) shares accounts for 4.83% of the company’s 30.80M shares outstanding.
It has a market capitalization of $5.52M and a beta (3y monthly) value of 0.65. The earnings-per-share (ttm) stands at -$38.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.82% over the week and 9.87% over the month.
Analysts forecast that Biolase Inc (BIOL) will achieve an EPS of -$0.89 for the current quarter, -$0.47 for the next quarter and -$0.1 for 2025. The lowest estimate earnings-per-share for the quarter is -$1.42 while analysts give the company a high EPS estimate of -$0.36. Comparatively, EPS for the current quarter was -$18 a year ago. Earnings per share for the fiscal year are expected to increase by 98.91%, and 65.62% over the next financial year. EPS should shrink at an annualized rate of 20.00% over the next five years, compared to 59.23% over the past 5-year period.
Looking at the support for the BIOL, a number of firms have released research notes about the stock. The Benchmark Company stated their Speculative Buy rating for the stock in a research note on June 19, 2019, with the firm’s price target at $2. Singular Research coverage for the Biolase Inc (BIOL) stock in a research note released on April 25, 2017 offered a Buy rating with a price target of $2.50. WallachBeth was of a view on May 13, 2014 that the stock is Hold, while WallachBeth gave the stock Buy rating on November 12, 2013, issuing a price target of $3.50- $2.75. WallachBeth on their part issued Buy rating on August 08, 2013.
